Header Logo

Connection

MICHAEL ITTMANN to Cell Proliferation

Back to Details
This is a "connection" page, showing publications MICHAEL ITTMANN has written about Cell Proliferation.
MICHAEL ITTMANN
Connection Strength
1.559
Cell Proliferation
  1. Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression. Cancer Invest. 2015 Jul; 33(6):251-8.
    View in: PubMed
    Score: 0.273
  2. RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression. Cancer Res. 2017 08 15; 77(16):4247-4257.
    View in: PubMed
    Score: 0.079
  3. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. Oncotarget. 2017 Jan 24; 8(4):6179-6192.
    View in: PubMed
    Score: 0.077
  4. FGF23 promotes prostate cancer progression. Oncotarget. 2015 Jul 10; 6(19):17291-301.
    View in: PubMed
    Score: 0.069
  5. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1a-mediated metabolic switch. Oncogene. 2014 Nov 06; 33(45):5251-61.
    View in: PubMed
    Score: 0.062
  6. Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. Clin Cancer Res. 2014 Jan 01; 20(1):100-9.
    View in: PubMed
    Score: 0.061
  7. A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis. Oncogene. 2014 Jun 12; 33(24):3099-108.
    View in: PubMed
    Score: 0.060
  8. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 2013 Apr 15; 73(8):2551-62.
    View in: PubMed
    Score: 0.059
  9. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression. Clin Cancer Res. 2012 Jul 15; 18(14):3880-8.
    View in: PubMed
    Score: 0.056
  10. Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res. 2011 Feb 15; 71(4):1325-33.
    View in: PubMed
    Score: 0.050
  11. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008 Oct 15; 68(20):8516-24.
    View in: PubMed
    Score: 0.043
  12. Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol. 2007 Feb; 38(2):299-307.
    View in: PubMed
    Score: 0.038
  13. Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. Cell Rep. 2025 Jun 24; 44(6):115792.
    View in: PubMed
    Score: 0.034
  14. Overexpression of POFUT1 promotes malignant phenotype and mediates perineural invasion in head and neck squamous cell carcinoma. Cell Biol Int. 2023 Dec; 47(12):1950-1963.
    View in: PubMed
    Score: 0.030
  15. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. Cell Oncol (Dordr). 2022 Feb; 45(1):41-56.
    View in: PubMed
    Score: 0.027
  16. CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. Neoplasia. 2021 11; 23(11):1147-1165.
    View in: PubMed
    Score: 0.027
  17. CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis. Prostate Cancer Prostatic Dis. 2021 09; 24(3):891-902.
    View in: PubMed
    Score: 0.026
  18. Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. Oncogene. 2021 03; 40(9):1690-1705.
    View in: PubMed
    Score: 0.025
  19. Spatially Restricted Stromal Wnt Signaling Restrains Prostate Epithelial Progenitor Growth through Direct and Indirect Mechanisms. Cell Stem Cell. 2019 05 02; 24(5):753-768.e6.
    View in: PubMed
    Score: 0.022
  20. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein. Oncogene. 2017 08 17; 36(33):4767-4777.
    View in: PubMed
    Score: 0.020
  21. SPOP Mutation Drives Prostate Tumorigenesis In?Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell. 2017 03 13; 31(3):436-451.
    View in: PubMed
    Score: 0.019
  22. Cellular interactions of the phosphorylated form of AKT in prostate cancer. Hum Pathol. 2017 05; 63:98-109.
    View in: PubMed
    Score: 0.019
  23. CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. Nat Commun. 2016 11 21; 7:13362.
    View in: PubMed
    Score: 0.019
  24. Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor. Mol Cell. 2016 09 15; 63(6):976-89.
    View in: PubMed
    Score: 0.019
  25. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. J Clin Invest. 2016 07 01; 126(7):2626-41.
    View in: PubMed
    Score: 0.018
  26. Role of miR-145 in human laryngeal squamous cell carcinoma. Head Neck. 2016 Feb; 38(2):260-6.
    View in: PubMed
    Score: 0.017
  27. Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors. PLoS One. 2015; 10(6):e0128467.
    View in: PubMed
    Score: 0.017
  28. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18261-6.
    View in: PubMed
    Score: 0.017
  29. Stromal TGF-? signaling induces AR activation in prostate cancer. Oncotarget. 2014 Nov 15; 5(21):10854-69.
    View in: PubMed
    Score: 0.017
  30. Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells. PLoS One. 2014; 9(9):e106289.
    View in: PubMed
    Score: 0.016
  31. Increased Notch signalling inhibits anoikis and stimulates proliferation of prostate luminal epithelial cells. Nat Commun. 2014 Jul 22; 5:4416.
    View in: PubMed
    Score: 0.016
  32. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A. 2014 Feb 04; 111(5):E592-600.
    View in: PubMed
    Score: 0.016
  33. FGFR1-WNT-TGF-? signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res. 2014 Jan 15; 74(2):609-20.
    View in: PubMed
    Score: 0.015
  34. Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.
    View in: PubMed
    Score: 0.015
  35. ERManI is a target of miR-125b and promotes transformation phenotypes in hepatocellular carcinoma (HCC). PLoS One. 2013; 8(8):e72829.
    View in: PubMed
    Score: 0.015
  36. MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. J Neurooncol. 2013 Nov; 115(2):143-51.
    View in: PubMed
    Score: 0.015
  37. The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer. Cancer Res. 2013 Jul 01; 73(13):3997-4008.
    View in: PubMed
    Score: 0.015
  38. SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer. Mol Endocrinol. 2013 Jun; 27(6):925-39.
    View in: PubMed
    Score: 0.015
  39. ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity. Mol Cancer Res. 2013 Jul; 11(7):736-47.
    View in: PubMed
    Score: 0.015
  40. Notch and TGF? form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell. 2012 Nov 02; 11(5):676-88.
    View in: PubMed
    Score: 0.014
  41. The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol. 2011 Apr 15; 6:39.
    View in: PubMed
    Score: 0.013
  42. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.
    View in: PubMed
    Score: 0.012
  43. SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem. 2010 Aug 13; 285(33):25859-66.
    View in: PubMed
    Score: 0.012
  44. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 2009 Apr; 1160:379-80.
    View in: PubMed
    Score: 0.011
  45. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
    View in: PubMed
    Score: 0.011
  46. Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer. 2008 Aug 01; 123(3):543-51.
    View in: PubMed
    Score: 0.011
  47. Relaxin promotes prostate cancer progression. Clin Cancer Res. 2007 Mar 15; 13(6):1695-702.
    View in: PubMed
    Score: 0.010
  48. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006 Nov 01; 66(21):10594-602.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.